gsk

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III ...
gsk

GSK showcases pipeline momentum across lung, gynaecological and gastrointestinal cancers at ESMO 2026

AZUR-1 data to show clinically meaningful sustained complete responses with Jemperli (dostarlimab) in MSI-H/dMMR locally advanced rectal cancer GSK plc (LSE/NYSE: GSK) will present more than 20 ...
gsk

Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China

GSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd., today announced positive overall survival (OS) data from ARTEMIS-008, its pivotal phase III trial in China evaluating the ...
gsk

Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) for ...
gsk

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy, across diverse populations Findings build on 10 years of ...
gsk

GSK completes acquisition of Nuvalent, Inc.

GSK plc (LSE/NYSE: GSK) today announced completion of its acquisition of Nuvalent, Inc. 1, a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology ...
gsk

GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population

ARTEMIS-008, a phase III study conducted for China, met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer First positive phase III overall survival data for a ...
gsk

GSK announces commencement of tender offer to acquire Nuvalent, Inc.

GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. (“Purchaser”), a direct wholly-owned subsidiary of ‎GlaxoSmithKline LLC (“GSK LLC”), which is an ‎indirect wholly-owned ...
gsk

GSK enters agreement to acquire Nuvalent, Inc.

Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies Includes two late-stage, potential best-in-class ...
gsk

Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)

Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP Approval based on ANCHOR trials showing clinically meaningful and statistically significant improvements in nasal polyp ...
gsk

Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B

Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials An estimated 75 million people in China live with chronic hepatitis ...
gsk

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

Lynavoy, an ileal bile acid transporter (IBAT) inhibitor, is the first medicine approved in the US for the treatment of cholestatic pruritus in patients with PBC Up to 89% of people living with PBC ...